---
title: "Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q3 Revenue: USD 17.63 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265942744.md"
datetime: "2025-11-14T13:37:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265942744.md)
  - [en](https://longbridge.com/en/news/265942744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265942744.md)
---

# Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q3 Revenue: USD 17.63 M

Revenue: As of FY2025 Q3, the actual value is USD 17.63 M.

EPS: As of FY2025 Q3, the actual value is USD 0.11.

EBIT: As of FY2025 Q3, the actual value is USD -4.805 M.

### Segment Revenue

-   Total net revenue increased by 20.5% to $17.6 million for the third quarter of 2025 compared to the third quarter of 2024.
-   Journey Medical’s net product revenues for the third quarter ended September 30, 2025, were $17.0 million, compared to $14.6 million for the third quarter ended September 30, 2024.

### Operational Metrics

-   Consolidated net income attributable to common stockholders was $3.7 million, or $0.13 per share basic, and $0.11 per share diluted, for the third quarter ended September 30, 2025, compared to a net loss of - $15.0 million, or - $0.76 per share basic and diluted, for the third quarter ended September 30, 2024.
-   Consolidated research and development expenses totaled $0.2 million for the third quarter ended September 30, 2025, compared to $9.4 million for the third quarter ended September 30, 2024.
-   Consolidated selling, general and administrative costs were $17.4 million for the third quarter ended September 30, 2025, compared to $22.0 million for the third quarter ended September 30, 2024.

### Cash Flow

-   As of September 30, 2025, Fortress’ consolidated cash and cash equivalents totaled $86.2 million, compared to $57.3 million as of December 31, 2024, an increase of $28.9 million year-to-date.

### Unique Metrics

-   Fortress received approximately $28 million upfront from the acquisition of Checkpoint by Sun Pharma, with the potential for an additional CVR payment of up to $4.8 million and a 2.5% royalty on future net sales of UNLOXCYT (cosibelimab-ipdl).

### Outlook / Guidance

-   Fortress anticipates the resubmission of the New Drug Application for CUTX-101, which may qualify for a Priority Review Voucher upon approval.
-   The company remains focused on disciplined execution, optimizing capital allocation, and advancing high-impact assets to drive sustainable growth and deliver innovative treatments to patients worldwide.

### Related Stocks

- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Argenx (ENXTBR:ARGX) Stock Valuation After Expanded FDA Approval For Vyvgart And Pipeline Progress](https://longbridge.com/en/news/289661572.md)
- [Mark Zuckerberg's Net Worth Crashes $31 Billion This Year, But Analysts Still Bullish on Meta](https://longbridge.com/en/news/289670977.md)
- [Should Alcoa’s Quebec Wharf 17 Logistics Upgrade Prompt Reassessment From Alcoa (AA) Investors?](https://longbridge.com/en/news/289661460.md)
- [Langdon Equity Partners Acquires New Holdings in Goosehead Insurance $GSHD](https://longbridge.com/en/news/289662511.md)
- [UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 126,120 Shares of McKesson Corporation $MCK](https://longbridge.com/en/news/289662493.md)